RayzeBio

aid: rayzebio
name: RayzeBio
description: RayzeBio is a clinical-stage radiopharmaceutical therapeutics company headquartered at 5505 Morehouse Drive,
  Suite 300, San Diego, California, and since 2024 a wholly owned Bristol Myers Squibb company. It develops targeted radiopharmaceutical
  therapies (RPTs) built on the alpha-emitting isotope actinium-225, led by RYZ101 (225Ac-DOTATATE) against somatostatin receptor
  2 (SSTR2)-expressing tumors including gastroenteropancreatic neuroendocrine tumors, extensive-stage small cell lung cancer
  and hormone-receptor-positive breast cancer, alongside earlier programs targeting glypican-3 (GPC3) in hepatocellular carcinoma
  and ACP3, plus paired diagnostic imaging agents such as [68Ga]Ga-RAYZ-8009. Its public web presence is a WordPress corporate
  marketing site covering discovery capabilities, radioisotope manufacturing, the pipeline, posters and presentations, leadership
  and careers; the company operates no developer program and publishes no API, SDK, or machine-readable specification, and
  is profiled here for network completeness rather than for an API surface.
url: https://raw.githubusercontent.com/api-evangelist/rayzebio/refs/heads/main/apis.yml
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://rayzebio.com/wp-content/uploads/2024/04/rayzebio_logo_grt_gry-300x122.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Radiopharmaceuticals
- Life Sciences
- Healthcare
- Clinical Trials
- Drug Discovery
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/rayzebio-domain-security.yml
- type: Website
  url: https://rayzebio.com/
- type: About
  url: https://rayzebio.com/about/about-overview/
- type: Team
  url: https://rayzebio.com/about/team/
- type: Contact
  url: https://rayzebio.com/contact/
- type: Careers
  url: https://rayzebio.com/careers/
- type: BlogRSS
  url: https://rayzebio.com/feed/
- type: PrivacyPolicy
  url: https://rayzebio.com/privacy-policy/
- type: TermsOfService
  url: https://rayzebio.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/rayzebio/
- type: ParentCompany
  url: https://www.bms.com/
- type: SecondaryMarketListing
  url: https://forgeglobal.com/rayzebio_stock/
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: 'RayzeBio is a clinical-stage radiopharmaceutical drug developer, now a Bristol Myers Squibb company, whose entire
    public surface is a 25-page WordPress marketing site — /openapi.json, /openapi.yaml, /swagger.json, /api-docs, /graphql,
    /llms.txt and every /.well-known/* path return a real 404, no GitHub org or npm/PyPI package exists under the name, and
    the only machine-readable endpoint on the host is the default WordPress /wp-json/ CMS route index (209 core/plugin routes:
    wp/v2, yoast, akismet, contact-form-7, wpe cache), which is WordPress plumbing and not a RayzeBio API product.'
  evidence:
  - url: https://rayzebio.com/openapi.json
    status: 404
  - url: https://rayzebio.com/graphql
    status: 404
  - url: https://rayzebio.com/.well-known/agent-card.json
    status: 404
  - url: https://rayzebio.com/llms.txt
    status: 404
  - url: https://rayzebio.com/wp-json/
    status: 200
  - url: https://api.github.com/orgs/rayzebio
    status: 404
  - url: https://rayzebio.com/media/news-new/
    status: 301
  checked: '2026-08-26'